Neratinib + Loperamide + Colesevelam
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early-stage Breast Cancer
Conditions
Early-stage Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive
Trial Timeline
Aug 31, 2022 → Jan 1, 2030
NCT ID
NCT05252988About Neratinib + Loperamide + Colesevelam
Neratinib + Loperamide + Colesevelam is a phase 2 stage product being developed by Puma Biotechnology for Early-stage Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05252988. Target conditions include Early-stage Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive.
What happened to similar drugs?
1 of 6 similar drugs in Early-stage Breast Cancer were approved
Approved (1) Terminated (1) Active (5)
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05252988 | Phase 2 | Active |
Competing Products
9 competing products in Early-stage Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anastrozole + Trastuzumab Deruxtecan | Daiichi Sankyo | Phase 2 | 42 |
| ICG | Johnson & Johnson | Pre-clinical | 26 |
| SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection | Jiangsu Hengrui Medicine | Phase 3 | 47 |
| Tamoxifen alone + Tamoxifen + Aminoglutethimide | AstraZeneca | Phase 3 | 40 |
| Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + Tamoxifen | AstraZeneca | Phase 3 | 40 |
| ABP 234 + Pembrolizumab | Amgen | Phase 3 | 47 |
| Rotigotine | UCB | Phase 3 | 40 |
| UCB0599 + Placebo | UCB | Phase 2 | 35 |
| Rasagiline + Pramipexole | Lundbeck | Approved | 32 |